These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 11248528

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [Abstract] [Full Text] [Related]

  • 5. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN, Pfaller MA, SENTRY Antimicrobial Surveillance Program Participants Group (USA).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.
    Deshpande L, Biedenbach DJ, Jones RN.
    Int J Antimicrob Agents; 2001 Nov; 18(5):437-40. PubMed ID: 11711258
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
    Korten V, Tomayko JF, Murray BE.
    Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M, Prieto N, Domingo D, de las Cuevas C, Sánchez I, Alarcón T.
    Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM, Singh KV, Murray BE.
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC.
    Am J Med; 1991 Dec 30; 91(6A):15S-18S. PubMed ID: 1662886
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM, Mazzucco CE, Lawrence LE, Ho H, Warr G, Barrett JF, Frosco M.
    Eur J Clin Microbiol Infect Dis; 2002 Jan 30; 21(1):27-34. PubMed ID: 11913498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.